• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Analyzing AD and allergies

Article

An ongoing longitudinal study is investigating whether early and continued treatment of atopic dermatitis with the topical immunomodulator pimecrolimus 1 percent cream (Elidel, Novartis) can prevent future development of asthma and other allergies. The multicenter trial was launched more than three years ago and randomized 1,091 children ages 3 months to 18 months old. An analysis of the demographic features of the study population highlights the value of the cohort for investigating a number of questions about AD and allergies.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.